The anti-PD-1 antibody drug BMS-936558 (Bristol-Myers Squibb) demonstrated encouraging results in a phase I clinical trial as a targeted immune therapy for patients who had been heavily treated for several forms of solid tumors.

©2012 American Association for Cancer Research.
2012
You do not currently have access to this content.